Mitsubishi UFJ Morgan Stanley Securities Co. Ltd. Purchases Shares of 18,300 Johnson & Johnson (NYSE:JNJ)

Mitsubishi UFJ Morgan Stanley Securities Co. Ltd. acquired a new position in shares of Johnson & Johnson (NYSE:JNJ) during the second quarter, Holdings Channel reports. The fund acquired 18,300 shares of the company’s stock, valued at approximately $2,675,000. Johnson & Johnson accounts for approximately 33.9% of Mitsubishi UFJ Morgan Stanley Securities Co. Ltd.’s portfolio, making the stock its 2nd largest holding.

Other large investors also recently made changes to their positions in the company. GUNN & Co INVESTMENT MANAGEMENT INC. lifted its stake in shares of Johnson & Johnson by 1,194.9% in the fourth quarter. GUNN & Co INVESTMENT MANAGEMENT INC. now owns 237,273 shares of the company’s stock valued at $37,190,000 after buying an additional 218,949 shares in the last quarter. Gilbert & Cook Inc. raised its holdings in shares of Johnson & Johnson by 3.3% in the 4th quarter. Gilbert & Cook Inc. now owns 9,111 shares of the company’s stock worth $1,428,000 after acquiring an additional 288 shares during the last quarter. Concentrum Wealth Management lifted its position in Johnson & Johnson by 5.1% in the 4th quarter. Concentrum Wealth Management now owns 2,193 shares of the company’s stock valued at $344,000 after acquiring an additional 106 shares in the last quarter. Westover Capital Advisors LLC increased its holdings in Johnson & Johnson by 5.8% during the 4th quarter. Westover Capital Advisors LLC now owns 3,328 shares of the company’s stock worth $522,000 after purchasing an additional 182 shares in the last quarter. Finally, Smart Money Group LLC increased its holdings in Johnson & Johnson by 9.0% during the 4th quarter. Smart Money Group LLC now owns 3,865 shares of the company’s stock worth $606,000 after purchasing an additional 318 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently issued reports on JNJ. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 16th. Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Daiwa Capital Markets downgraded shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $160.00 to $150.00 in a report on Tuesday, July 23rd. Sanford C. Bernstein lifted their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Finally, The Goldman Sachs Group reduced their target price on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a report on Friday, July 19th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Stock Up 0.1 %

Shares of NYSE JNJ opened at $167.27 on Thursday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The stock has a market capitalization of $402.57 billion, a PE ratio of 10.43, a P/E/G ratio of 2.73 and a beta of 0.52. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85. The business’s fifty day moving average price is $156.82 and its 200-day moving average price is $153.70.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating the consensus estimate of $2.71 by $0.11. The business had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company’s revenue was up 4.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.80 earnings per share. On average, equities research analysts anticipate that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a yield of 2.97%. Johnson & Johnson’s dividend payout ratio is 30.92%.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.